SCHEMBL2850768

SCHEMBL2850768

COc1ccc(-c2cc[c]cc2)c(O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
GFER P55789 1/20 0.49
NPC1 O15118 4/20 0.47
NOTUM Q6P988 1/20 0.46
RAB9A P51151 3/20 0.46
MAPT P10636 4/20 0.46
MAPK1 P28482 3/20 0.46
NCOA1 Q15788 2/20 0.46
NCOA3 Q9Y6Q9 2/20 0.46
TP53 P04637 2/20 0.46
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
MAPK10 P53779 1/20 0.46
PTK2B Q14289 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
BACE1 P56817 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
ALDH1A1 P00352 2/20 0.44
TRIM24 O15164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7622171 0.82 ESR2 (0.65) KMT2AMEN1GFERNPC1RAB9A
SCHEMBL22280547 0.82 ESR2 (0.65) KMT2AMEN1GFERNPC1NOTUM
SCHEMBL13674387 0.82 NPC1 (0.55) KMT2AMEN1GFERNPC1NOTUM
SCHEMBL5917522 0.81 SMN1; SMN2 (0.41) KMT2AMEN1RAB9AMAPTHTT
SCHEMBL696108 0.81 CYP1A1 (0.62) KMT2AMEN1GFERNPC1RAB9A
SCHEMBL11192923 0.81 BACE1 (0.66) KMT2AMEN1GFERNPC1RAB9A
SCHEMBL23754816 0.81 NPC1 (0.44) KMT2AMEN1GFERNPC1NOTUM
SCHEMBL27571276 0.80 NPC1 (0.46) KMT2AMEN1GFERNPC1NOTUM
SCHEMBL340086 0.80 NPC1 (0.60) KMT2AMEN1GFERNPC1NOTUM
SCHEMBL9457332 0.78 ALOX5 (0.61) KMT2AMEN1MAPTHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110505868-A Personal care compositions WEIDMANN HOLDING AG 2019-11-26 CN disclosed
CN-108314980-A A kind of adhesive and its application method 东莞市科惠工业材料有限公司 2018-07-24 CN disclosed
EP-2252154-B1 METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL OY GRANULA AB LTD (FI) 2016-01-27 EP disclosed
CN-103467936-B A kind of Absorbable rod also transforms PET film of UV-light and shortwave blue light and preparation method thereof SUZHOU KINGHIGH MEMBRANE TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2016-01-20 CN disclosed
EP-2850113-A1 NOVEL POLYMERIC PHOTOINITIATORS AND PHOTOINITIATOR MONOMERS Coloplast A/S (DK) 2015-03-25 EP disclosed
CN-103467936-A PET (polyethylene terephthalate) film capable of absorbing and converting ultraviolet light and shortwave blue light and preparation method thereof SUZHOU KINGHIGH MEMBRANE TECHNOLOGY DEV CO LTD 2013-12-25 CN disclosed
WO-2013170857-A1 NOVEL POLYMERIC PHOTOINITIATORS AND PHOTOINITIATOR MONOMERS COLOPLAST A/S (DK) 2013-11-21 WO disclosed
US-8496974-B2 Method for preparing a composition comprising a compound mixture and a carrier agent OY GRANULA AB LTD (FI) 2013-07-30 US disclosed
EP-2252154-A2 METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL Oy Granula AB LTD (FI) 2010-11-24 EP disclosed
US-20100129304-A1 METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND MIXTURE AND A CARRIER AGENT OY GRANULA AB LTD (FI) 2010-05-27 US disclosed
WO-2009101261-A2 METHOD FOR MINIMIZING THE CYTOTOXICITY OF THE EFFECTIVE AGENT IN A COMPOSITION THAT IS ADMINISTERED TO A MAMMAL OR GETS INTO CONTACT WITH A MAMMAL OY GRANULA AB LTD (FI) 2009-08-20 WO disclosed
EP-1802599-A2 HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS The Ohio State University Research Foundation (US) 2007-07-04 EP disclosed
WO-2007001348-A2 HETEROARYL-CONTAINING ISOFLAVONES AS AROMATASE INHIBITORS THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) 2007-01-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100129304-A1 METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND MIXTURE AND A CARRIER AGENT H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, BAK1, PMAIP1 KMT2A 2163/4885MEN1 3431/4885GFER 3609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.